As a full service CRO, CYTE supports and enhances conduct of international clinical trials and outcomes research for clients. The Thrombosis Research Institute (TRI) partnered with CYTE for support in the set up and management of three major registries in recent years. In early 2020 the registries were successfully closed out.
A brief overview of each registry:
- GARFIELD-AF is the world’s largest prospective registry of patients with newly diagnosed atrial fibrillation. The study included >57,000 patients in 40 countries.
- GARFIELD-VTE explored acute and long-term management and outcomes in VTE patients treated in a real-world setting. The study included >10,000 patients in more than 20 countries.
- The RIVER Registry focuses on the use of Rivaroxaban and the management of atrial fibrillation and stroke management in real world settings. The registry included >5000 patients
Note: aside from publications in leading journals, key insights from the GARFIELD registries have been disseminated in the GARFIELD in Focus newsletter, all editions of which are available for download here. You can learn more about the Thrombosis Research Institute at http://www.tri-london.ac.uk/